May 01, 2017
The Third Circuit on Monday nixed a False Claims Act suit accusing Genentech Inc. of defrauding Medicare by concealing side effects of its blockbuster cancer drug Avastin, saying a whistleblower didn't show that failing to report safety information was relevant to government reimbursement for the medication.